Skip to main content

Table 1 Patient characteristics according to subgroup of weight variation during chemotherapy. (p represents the p-value based on ANOVA, Welch’s ANOVA, or Kruskal-Wallis test for continuous data, and the Chi-squared test for categorical data)

From: A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients

 OverallGAINSTABLELOSSp
Overall 
 n n n n  
Median age (range) — yrs10948 (25–74)3248 (26–62)6649 (25–74)1161 (40–70)0.024
Mean weight (SD) — kg
 At baseline10966.5 (15.2)3260.2 (8.9)6667.1 (14.8)1181.5 (21.5)0.01
 At the end of chemotherapy10967.5 (14)3265.3 (9.8)6667.5 (14.6)1173.8 (19.6)0.686
 At the end of Herceptin®10967.1 (14.5)3263.9 (9.7)6167.6 (15.1)1073.8 (21.3)0.212
BMI (SD) — kg/m2
 At baseline10925.1 (5.7)3222.6 (3.7)6625.3 (5.2)1131.2 (8.4)0.005
 At the end of chemotherapy10925.5 (5.3)3224.5 (4.1)6625.5 (5.2)1128.3 (7.8)0.579
 At the end of Herceptin®10925.3 (5.5)3224.0 (4.1)6125.5 (5.4)1028.5 (8.5)0.148
Contraceptive status — %0.203
 Yes5247.71959.43045.5327.3 
 No109.239.469.119.1
 Sterile1211412.5812.100
 Menopaused3532.1618.82233.3763.6
Tumor — %
pT0.078
 T28477.12371.95583.3654.5 
 T32522.9928.11116.7545.5
pN0.048
 N05045.9928.13654.5545.5 
 N15954.12371.93045.5654.5
M0.745
 M010596.33196.96395.511100 
 Mx43.713.134.500
SBR grade0.36
 I10.913.10000 
 II5045.91134.43350654.5
 III5651.41959.43248.5545.5
 Unknown21.813.111.500
IHC results 
 Overexpressed10697.2321006395.511100 
 Non-determined32.80034.500
Treatment — %
 Docetaxel + Trastuzumab + Bevacizumab3532.1721.92334.8545.5 
 Docetaxel + Trastuzumab7467.92578.14365.2654.5